Fuse Science Inc (DROP) financial statements (2020 and earlier)

Company profile

Business Address 5510 MERRICK RD.
MASSAPEQUA, NY 11758
State of Incorp. NV
Fiscal Year End September 30
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2015
TTM
9/30/2014
9/30/2013
9/30/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 000
Cash and cash equivalents 000
Receivables  00
Inventory, net of allowances, customer advances and progress billings  10
Inventory  10
Prepaid expense  0
Prepaid expense and other current assets0
Other undisclosed current assets 0  
Total current assets: 011
Noncurrent Assets
Property, plant and equipment 000
Intangible assets, net (including goodwill)  00
Intangible assets, net (excluding goodwill)  00
Prepaid expense and other noncurrent assets0
Total noncurrent assets: 000
TOTAL ASSETS: 021
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 121
Accounts payable 121
Accrued liabilities  00
Debt 000
Derivative instruments and hedges, liabilities  0 
Other undisclosed current liabilities  (0)(0)
Total current liabilities: 121
Noncurrent Liabilities
Long-term debt and lease obligation   0
Long-term debt, excluding current maturities   0
Liabilities, other than long-term debt 1  
Derivative instruments and hedges, liabilities 1  
Other undisclosed noncurrent liabilities  0 
Total noncurrent liabilities: 100
Total liabilities: 221
Stockholders' equity
Stockholders' equity attributable to parent (2)(1)(0)
Common stock 000
Additional paid in capital 504423
Accumulated deficit (52)(44)(23)
Stockholders' equity attributable to noncontrolling interest (0)(0)(0)
Total stockholders' equity: (2)(1)(0)
TOTAL LIABILITIES AND EQUITY: 021

Income statement (P&L) ($ in millions)

6/30/2015
TTM
9/30/2014
9/30/2013
9/30/2012
Revenues 000
Revenue, net 000
Cost of revenue
(Cost of Goods and Services Sold)
  (0) 
Other undisclosed gross profit (1)  
Gross profit: (1)00
Operating expenses (4)(9)(8)
Other undisclosed operating income  00
Operating loss: (5)(9)(7)
Nonoperating expense (2)(13)(4)
Debt instrument, convertible, beneficial conversion feature   (1)
Interest and debt expense (0)(3)(3)
Loss from continuing operations before income taxes: (8)(24)(14)
Income tax expense (3) (4)
Loss before gain (loss) on sale of properties: (11)(24)(18)
Other undisclosed net income 337
Net loss available to common stockholders, diluted: (8)(21)(11)

Comprehensive Income ($ in millions)

6/30/2015
TTM
9/30/2014
9/30/2013
9/30/2012
Net loss: (8)(21)(11)
Comprehensive loss, net of tax, attributable to parent: (8)(21)(11)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: